Press Releases

Jun 14, 2026

Maya Rios

Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex Therapeutics reported positive Phase 1 clinical trial results for CDX-622, a novel bispecific antibody targeting soluble stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP) pathways. The study demonstrated rapid, dose-dependent mast cell depletion and TSLP inhibition with good tolerability and safety in healthy participants, supp…

CLDX

Jun 14, 2026

Leila Farooq

Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Legend Biotech presented encouraging early clinical data for LB2501, their investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, showing 100% objective response and 83.3% complete response rates at the higher dose in a Phase 1 trial for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy demonstrated dose-dependent CAR-T expansio…

LEGN

Jun 13, 2026

Nina Shah

Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Ascendis Pharma announced positive Phase 3 PaTHway trial results demonstrating that TransCon PTH provides sustained normalization of biochemical markers, improved kidney function, bone density, and quality of life in adults with hypoparathyroidism over 182 weeks. The treatment enabled patients to discontinue conventional therapies such as active vi…

ASND

Jun 13, 2026

Derek Hwang

Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Agios Pharmaceuticals presented detailed results from its RISE UP Phase 3 trial of mitapivat, showing statistically significant hemoglobin improvement and clinically meaningful reductions in transfusion burden and sickle cell pain crises among responders. The data reinforces mitapivat's strong anti-hemolytic profile and potential to improve quality…

AGIO

Jun 13, 2026

Maya Rios

Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals announced encouraging interim six-month data from their Phase 2 trial of setmelanotide in patients with Prader-Willi Syndrome (PWS), demonstrating clinically meaningful reductions in BMI, fat mass, hyperphagia scores, and anxiety measures. These results strengthen the case for advancing setmelanotide, an MC4R agonist, into Ph…

RYTM

Jun 13, 2026

Maya Rios

Press Releases

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics reported additional positive results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene-editing therapy for hereditary angioedema (HAE). The treatment demonstrated an 87% reduction in monthly HAE attacks versus placebo and a favorable safety profile. The data were presented at EAACI …

NTLA

Jun 12, 2026

Sofia Navarro

Press Releases

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Arcadia Biosciences (Nasdaq: RKDA) successfully closed a $4 million private placement by issuing common stock and preferred investment options at $1.03 per share, with gross proceeds intended for working capital and general corporate purposes. The offering was conducted under Section 4(a)(2) of the Securities Act and accompanied by registration rig…

RKDA

Jun 12, 2026

Derek Hwang

Press Releases

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio, a clinical-stage US biopharmaceutical company, has completed the rolling submission of its New Drug Application to the FDA for tinlarebant, an investigational oral therapy targeting Stargardt disease type 1 (STGD1), a rare inherited retinal disorder with no approved treatments. The submission leverages multiple expedited regulatory desi…

BLTE

Jun 12, 2026

Jordan Park

Press Releases

ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical

ROMA Green Finance has announced the creation of a dedicated investment vertical focused on Artificial Intelligence and High-Performance Computing infrastructure, emphasizing energy-efficient, low-carbon digital assets paired with behind-the-meter power generation. This move extends their sustainable finance and ESG advisory mandate into digital in…

ROMA

Jun 12, 2026

Sofia Navarro

Press Releases

Heartland Express, Inc. Declares Regular Quarterly Dividend

Heartland Express, Inc. announced the declaration of a regular quarterly cash dividend of $0.02 per share payable on July 6, 2026, marking the company's 92nd consecutive quarterly dividend payment. The total dividend payout is estimated at $1.6 million based on approximately 78 million shares outstanding, continuing a dividend program that began in…

HTLD

Jun 12, 2026

Priya Menon

Press Releases

Traws Pharma Provides Regulatory Update on Influenza Program

Traws Pharma announced the deferment of its planned Phase 2a human influenza challenge study for its lead antiviral candidate, tivoxavir marboxil (TXM), due to a negative review by the UK's MHRA. Despite the setback, the company remains committed to advancing TXM and other back-up influenza antiviral compounds with improved profiles, highlighting t…

TRAW

Jun 12, 2026

Marcus Reed

Press Releases

Lotus Tech Announces Operational and Earnings Reporting Updates

Lotus Technology Inc. announced progress on its strategic acquisition of Lotus UK aimed for 2026 closure, as part of its Focus 2030 strategy to unify brand and enhance operational efficiency. The company is temporarily suspending earnings releases for Q1 and Q3 of 2026 to prioritize acquisition compliance and integration, while continuing to report…

LOT

Jun 12, 2026

Leila Farooq

Press Releases

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, has elected to voluntarily delist its common shares from the TSX Venture Exchange. The company aims to eliminate duplicate exchange fees, reduce legal and accounting expenses, optimize financing initiatives, and simplify regulatory compliance by maintaining a single listing on t…

XRTX

Jun 12, 2026

Maya Rios

Press Releases

The Children’s Place Reports First Quarter 2026 Results

The Children's Place reported a Q1 2026 net sales decline of 11.1% to $215.2 million, with an operating loss of $42.2 million and net loss of $53.2 million. The company is implementing strategic initiatives focusing on customer experience, brand strength, financial targets, and leadership amid challenging retail conditions and higher tariff costs. …

PLCE

Jun 12, 2026

Avery Klein

Press Releases

Black Hills Corp. Requests Rate Review in Colorado

Black Hills Corp.'s Colorado electric utility has submitted a rate review application to the Colorado Public Utilities Commission seeking $26.7 million in additional annual revenue. This is to recover approximately $184 million invested since the last rate review, particularly aimed at improving reliability and strengthening the electric grid. The …

BKH

Jun 12, 2026

Jordan Park

Press Releases

Coffee Holding Company Reports Second Quarter Results.

Coffee Holding Co., Inc. reported second quarter fiscal results ending April 30, 2026, showing a 5.1% decline in net sales primarily due to a rapid 25% decline in green coffee prices. The company responded by lowering prices and increasing promotions for wholesale customers, which pressured sales volumes and profit margins. Gross profit decreased s…

JVA

Jun 12, 2026

Hana Yamamoto

Press Releases

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics announced a new employment inducement award granting 6,100 stock options to a new employee at an exercise price matching the recent closing price. The options vest over four years with a ten-year term, approved by the board under Nasdaq inducement rules. The company specializes in late-stage clinical cell therapies targeting …

RNAC

Jun 12, 2026

Maya Rios

Press Releases

Canterbury Park Holding Corporation Announces Quarterly Cash Dividend

Canterbury Park Holding Corporation announced a quarterly cash dividend of $0.07 per share, scheduled for payment on July 14, 2026, to shareholders of record as of June 30, 2026. This results in an annualized dividend of $0.28 per common share. The company operates Canterbury Park Racetrack and Casino in Minnesota and is pursuing development opport…

CPHC

Jun 12, 2026

Marcus Reed

Press Releases

XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

XOMA Royalty Corporation announced quarterly cash dividends for its Series A and Series B cumulative perpetual preferred stock, with payments scheduled for mid-July 2026. Furthermore, the company will redeem all outstanding preferred shares at $25 per share on July 14, 2026, ceasing dividend accrual thereafter. This redemption is in connection with…

XOMA

Jun 12, 2026

Maya Rios

Press Releases

Avista pauses processing of energy service request from 500 MW data center developer while seeking broader policy and community alignment

Avista Corp., a US energy company, has temporarily suspended processing the energy service request from a potential 500 MW data center developer amid community concerns and to seek broader alignment with governmental agencies and stakeholders. The company emphasizes the need for a coordinated planning process, regulatory approvals, and ensuring tha…

AVA

Jun 12, 2026

Derek Hwang

Press Releases

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD, Inc., developer of the CGuard Prime carotid stent system, announced inducement grants of 91,161 shares of restricted stock to six new non-executive employees as part of its 2024 Inducement Plan, approved under Nasdaq Listing Rule 5635(c)(4). The shares vest over three years contingent on continued employment. The company highlights ongoi…

NSPR

Jun 12, 2026

Marcus Reed

Press Releases

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Rhythm Pharmaceuticals announced a live webcast and conference call to discuss interim six-month results from its Phase 2 clinical trial of setmelanotide in patients with Prader-Willi syndrome. Setmelanotide is an FDA-approved MC4R agonist currently used to treat various rare genetic and hypothalamic obesity disorders. The company is expanding clin…

RYTM

Jun 12, 2026

Marcus Reed

Press Releases

Monolithic Power Systems Announces Second Quarter 2026 Dividend

Monolithic Power Systems, a Nasdaq-listed semiconductor company, announced a quarterly dividend of $2.00 per share for Q2 2026, payable on July 15, 2026. This dividend declaration underscores the company's robust financial health and commitment to returning value to shareholders. MPS specializes in high-performance semiconductor power electronics w…

MPWR

Jun 12, 2026

Leila Farooq

Press Releases

Village Super Market, Inc. Declares Quarterly Dividend

Village Super Market, Inc. declared quarterly dividends of $0.25 for Class A shares and $0.1625 for Class B shares, payable on July 23, 2026, to shareholders of record as of July 2, 2026. The company operates 34 supermarkets under ShopRite and Fairway banners and Gourmet Garage specialty markets across several states.

VLGEA

Jun 12, 2026

Priya Menon

Press Releases

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

Cosmos Health Inc., a diversified global healthcare company listed on NASDAQ under ticker COSM, announced that its subsidiary Cana Laboratories has received new contract manufacturing orders totaling 253,657 units across multiple pharmaceutical products. These orders come from partners Nassington and Verisfield, highlighting demand for Cana's manuf…

COSM